RECRUITINGINTERVENTIONAL
The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma
The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma: A Retrospective Study
About This Trial
This study aimed to reduce radiation-induced thyroid injury without compromising control of the cervical region by optimizing the delineation of the cervical lymph node drainage area.
Who May Be Eligible (Plain English)
Who May Qualify:
1. The pathological diagnosis was newly diagnosed non-keratinizing squamous cell carcinoma nasopharyngeal carcinoma.
2. The clinical stage is T1-4N0-3M0 (stage I\~IVa, UICC/AJCC 8th edition);
3. There is no history of hypothyroidism or hyperthyroidism before treatment;
4. Using intensity-modulated radiotherapy technology,
5. Complete radical dose radiotherapy;
6. KPS≥70 points;
7. Age 18-70 years old;
8. Male or female who is not pregnant or lactating;
9. Hematological examination: white blood cells \> 4×109/L, neutrophils \> 2×109/L, hemoglobin \> 90g/L, platelets \> 100×109/L;
10. Liver function: ALT, AST \< 1.5×ULN, ALP \< 2.5×ULN, bilirubin \< ULN.
11. Renal function: creatinine \> 60 ml/min;
12. The patient signs the willing to sign a consent form form;
Who Should NOT Join This Trial:
1. WHO pathological classification is keratinizing squamous cell carcinoma or basaloid carcinoma;
2. palliative treatment;
3. Have a history of other malignant tumors;
4. Pregnant or lactating women (women of childbearing age should consider taking a pregnancy test, and patients are required to use effective contraception during treatment);
5. Have a history of neck surgery;
6. Have a history of hyperthyroidism or hypothyroidism.
7. Previous history of head and neck radiation therapy;
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
1. The pathological diagnosis was newly diagnosed non-keratinizing squamous cell carcinoma nasopharyngeal carcinoma.
2. The clinical stage is T1-4N0-3M0 (stage I\~IVa, UICC/AJCC 8th edition);
3. There is no history of hypothyroidism or hyperthyroidism before treatment;
4. Using intensity-modulated radiotherapy technology,
5. Complete radical dose radiotherapy;
6. KPS≥70 points;
7. Age 18-70 years old;
8. Male or female who is not pregnant or lactating;
9. Hematological examination: white blood cells \> 4×109/L, neutrophils \> 2×109/L, hemoglobin \> 90g/L, platelets \> 100×109/L;
10. Liver function: ALT, AST \< 1.5×ULN, ALP \< 2.5×ULN, bilirubin \< ULN.
11. Renal function: creatinine \> 60 ml/min;
12. The patient signs the informed consent form;
Exclusion Criteria:
1. WHO pathological classification is keratinizing squamous cell carcinoma or basaloid carcinoma;
2. palliative treatment;
3. Have a history of other malignant tumors;
4. Pregnant or lactating women (women of childbearing age should consider taking a pregnancy test, and patients are required to use effective contraception during treatment);
5. Have a history of neck surgery;
6. Have a history of hyperthyroidism or hypothyroidism.
7. Previous history of head and neck radiation therapy;
Treatments Being Tested
RADIATION
Modified neck target volume delineation
Modified neck target volume delineation method was used to define the inner boundary of regions III and IVa as the outer edge of the common carotid artery.
Locations (1)
Department of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital
Nanchang, None Selected, China